MAPT and Alzheimer disease: As to tau, clinical trials of tau immunotherapies that use tau-targeted antibodies (such as semorinemab) to reduce phosphorylated tau levels in AD have started, and tau vaccines such as ACI-35 (by AC Immune) that stimulate the body to develop tau antibodies have also entered clinical trials (154, 155).